ABSTRACT
A latent HIV-1 reservoir is established in resting CD4
ϩ T cells early during acute infection (1) (2) (3) (4) (5) . This reservoir is unaffected by the immune system or by antiretroviral therapy (ART) but has the potential to produce infectious virus, which may contribute to persistent plasma viremia during ART or viral rebound if ART is interrupted. Therefore, HIV-1 cure strategies will need to include a therapeutic approach that eliminates, or significantly reduces the size of, this reservoir.
The resting CD4 ϩ T cell population is heterogeneous and includes naive (T N ), stem cell-like memory, central memory (T CM ), transitional memory (T TM ), effector memory (T EM ), and terminally differentiated cells. In HIV-1-infected individuals, viral DNA has been detected in all of these CD4 ϩ T cell subsets although the levels of total HIV-1 DNA are typically highest in the T CM and T TM cell compartments, suggesting that they may be the major reservoirs of latent viral infection (6) (7) (8) . However, recent analyses of the frequency of replication-competent virus in cells from infected individuals on suppressive ART, as measured by the quantitative viral outgrowth assay (QVOA), revealed that while replication-competent HIV-1 was consistently detected within T CM cells, it was not frequently detected in the T TM cell compartment (9) although this finding has not been consistently observed in other studies (6, 10) . This finding indicates that quantification of viral DNA alone is not necessarily predictive of the size of the inducible latent reservoir and suggests caution in labeling a cellular reservoir of latent HIV-1 as "major" based solely on the frequency of infection. In addition to the memory CD4 ϩ T cell subsets, HIV-1 DNA is almost always detected in T N cells in both viremic and suppressed individuals, although with a much lower frequency than in the T CM and T TM compartments (6, 7, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Interestingly, in 2013 Saez-Cirion et al. reported that in some HIV-1-infected individuals who received ART within 10 weeks of primary infection, viremia could be controlled for at least 24 months posttreatment interruption (8) . In this patient population, HIV-1 DNA was detected in CD4 ϩ T N cells in only 2 of 11 individuals, whereas all the resting memory CD4
ϩ T cell subsets (T CM , T TM , and T EM ) harbored comparable levels of HIV-1 DNA (8) . This finding suggests that the latent HIV-1 reservoir in CD4 ϩ T N cells may be more important than previously considered.
The naive and different resting memory CD4 ϩ T cell subsets differ in life span, proliferative capacity, antigen response time, residence throughout the body, and expression levels of their HIV-1 coreceptors, CCR5 and CXCR4 (22) (23) (24) . In light of this, we hypothesized that the establishment and reversal of HIV-1 latency would differ between naive and memory CD4 ϩ T cells and that understanding these phenotypes in different CD4
ϩ T cell subsets could facilitate the development of effective cure strategies to purge the latent reservoir. Given the low frequency of latently infected cells in ART-suppressed individuals, approximately 100 copies of HIV-1 DNA or one infectious unit per 10 6 resting CD4 ϩ T cells (25) (26) (27) , we sought to compare and contrast latent HIV-1 infection using a primary cell model in highly purified T N and T CM CD4 ϩ T cells.
MATERIALS AND METHODS

Purification of T N and T CM CD4
؉ T cells. A total of 180 ml of blood was obtained from healthy HIV-negative volunteers, which was approved by the University of Pittsburgh Institutional Review Board. Written informed consent was provided for all donors. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation. Resting CD4 ϩ T cells were purified by first isolating total CD4 ϩ T cells by magnetic bead negative selection using a CD4 ϩ T cell purification kit, followed by magnetic bead negative selection using anti-CD25, anti-CD69, and anti-HLA-DR antibodies. T N cells were isolated from the resting CD4 ϩ T cells by magnetic bead depletion of CD45RO ϩ cells. T CM cells were isolated from the resting CD4 ϩ T cells by magnetic bead depletion of CD45RA ϩ cells, followed by positive selection of CCR7-expressing cells. Increased labeling times were used to increase cell purity. All magnetic bead purification kits and antibodies were obtained from Miltenyi Biotec. The purity of the T N and T CM cells was assessed by flow cytometry (LSR II; BD Biosciences) using the following antibodies: CD3-V450, CD4-peridinin chlorophyll protein (PerCP)-Cy5.5, CD45RA-fluorescein isothiocyanate (FITC), CCR7-phycoerythrin (PE), CD27-allophycocyanin (APC)-H7, and CD62L-APC (BD Biosciences). Data were analyzed using FlowJo, version X.0.7. The T N and T CM cell surface phenotypes were as follows:
ϩ T N and T CM cell purity levels were always found to be Ն98% and Ն96%, respectively (Fig. 1A) .
Infection of T N and T CM CD4 ؉ T cells. Purified T N and T CM CD4 ϩ T cells were cultured at a density of 1 ϫ 10 6 to 2 ϫ 10 6 cells/ml in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, and 0.29 mg/ml glutamine (all from Life Technologies). CCL19 (100 nM final concentration) was added to the cells 2 days prior to infection with HIV-1, as described previously (28, 29) . Cells were infected with either the CXCR4-tropic strain HIV-1 LAI (30) or the CCR5-tropic strain HIV-1 BaL at a multiplicity of infection of 1 (titers were determined on GHOST cells) [31] ) for 2 to 3 h at 37°C. HIV-1 BaL was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from S. Gartner, R. C. Gallo, and M. Popovic (32) . Cells were then washed twice with fresh medium to remove free virus. Every 2 days following infection, 10 units/ml recombinant interleukin-2 (IL-2; Roche) was added to the medium, in addition to 300 nM efavirenz (EFV; NIH AIDS Reagent Program) to inhibit multiple rounds of HIV-1 infection. For some experiments, 300 nM raltegravir (RAL; NIH AIDS Reagent Program) was also included to block multiple rounds of HIV-1 infection.
Flow cytometry. T cell activation was assessed by flow cytometry using the following antibodies from BD Biosciences: CD3-V450, CD4-PerCPCy5.5, CD25-PE-Cy7, CD69-PE, and HLA-DR-FITC. To measure the expression of the HIV-1 coreceptors CCR5 and CXCR4, T N and T CM cells were stained with CD3-V450, CD4-PerCP-Cy5.5, and either CCR5-PE or CXCR4-PE (BD Biosciences). Typically, 50,000 to 100,000 cells were collected per sample in the CD3 ϩ CD4 ϩ gate to adequately measure CCR5 or CXCR4 expression. Dead cells were excluded based on plots of side scatter area (SSC-A) and forward scatter area (FSC-A). For some experiments where noted in the text, cell viability was determined using a Live/Dead fixable cell viability dye for flow cytometry (Invitrogen). The intracellular proliferation marker Ki-67 was stained according to the manufacturer's protocol (BD Biosciences). However, instead of using the cell viability solution (7-amino-actinomycin D ) to discriminate live cells from dead cells, we first stained the cells with Live/Dead-APC (Invitrogen) prior to fixation and permeabilization for Ki-67 staining. All samples were run on an LSR II instrument, and the data were analyzed using FlowJo, version X.0.7.
Extraction and quantification of HIV-1 DNA. Total cellular DNA was extracted from pooled duplicate culture wells and was assayed for total HIV-1 DNA and two-long terminal repeat (2-LTR) circle DNA levels by quantitative PCR (qPCR), as described previously (33, 34) . Each sample was run in triplicate using the LightCycler 480 System (Roche). DNA standards were included as described previously (33, 34) . HIV-1 DNA and 2-LTR circles were normalized to the total number of cells assayed by quantitative PCR amplification of the CCR5 gene (35) .
Integration site sequencing. Genomic DNA (20 g) was isolated using a DNeasy blood and tissue kit (Qiagen) from resting and phytohemagglutinin (PHA)-activated T N and T CM CD4 ϩ T cells infected with HIV-1 LAI . DNA was digested overnight with 100 U each of MseI and BglII and purified using a QIAquick PCR purification kit (Qiagen). Doublestranded asymmetric linkers were prepared by heating 10 M each oligonucleotide to 90°C in 10 mM Tris-HCl, pH 8.0, and 0.1 mM EDTA and slowly cooling them to room temperature. Linker DNA (1.5 M) was ligated with digested cellular DNA (1 g) overnight at 12°C with 800 U of T4 DNA ligase in four parallel reactions, and the DNAs were pooled and repurified using a QIAquick PCR purification kit. Seminested PCR was used to selectively amplify integration sites, with reactions multiplexed into eight separate samples per PCR stage. The first and second rounds of PCR utilized nested HIV-1 U5 primers, whereas the same linker-specific primer was used for both rounds. The linker primer and second-round U5 primer each encoded adapter sequences necessary for Illumina sequencing, as well as for sequencing primer binding sites. To allow the identification of unique library samples from multiplexed sequencing runs, unique bar-coded linker DNAs and linker-specific primers were employed for each sample, and the nested U5 primer additionally encoded a unique 6-bp index sequence. The sequences of the oligonucleotides utilized are provided in Table 1 . Each PCR mixture contained 100 ng of template DNA, 1.9 M U5 primer, and 0.375 M linker primer. Each reaction was carried out using Advantage 2 polymerase mix (Clontech), according to the manufacturer's instructions, and the reaction mixture was incubated at 94°C for 2 min, followed by 30 cycles at 94°C for 15 s, 55°C for 30 s, and 68°C for 45 s, with a final extension for 10 min at 68°C. Pooled PCR products were purified using a QIAquick PCR purification kit, and second-round reaction products were submitted for sequencing on the Illumina MiSeq platform at the Dana-Farber Cancer Institute Molecular Biology Core Facilities. Resulting sequences were mapped to the hg19 version of the human genome using BLAT, allowing for a minimum unique sequence identity match of 97%. Correlations of integration site distributions relative to various genomic features were conducted using BEDTools (36) . Statistical analysis of resulting integration frequencies was determined using R (37, 38) , with statistical significance being calculated by Fisher's exact test and a Wilcoxon rank sum test. 
The purity of each subset was determined by surface Quantification of F-actin density. Filamentous actin (F-actin) density was quantified by both flow cytometry and confocal microscopy. For flow cytometry, cells were first surface stained for CD3-V450 and CD4-PerCP-Cy5.5 (BD Biosciences); cells were then fixed in 1% paraformaldehyde (PFA), permeabilized with 0.1% Triton-X (Sigma-Aldrich) supplemented with 5% FBS, and stained with 100 nM phalloidin-FITC (100 nM; Sigma-Aldrich) in phosphate-buffered saline (PBS) supplemented with 5% FBS. Following staining, cells were washed with PBS supplemented with 5% FBS to remove any unbound phalloidin. All samples were run within 24 h on an LSR II system, and the data were analyzed using FlowJo software. A total of 10,000 events were collected per sample in the CD3 ϩ CD4 ϩ gate. Dead cells were excluded based on side scatter and forward scatter plots. Latrunculin A (Lat-A; Thermo Fisher) was added to cells 6 h prior to the addition of CCL19. At 48 h post-CCL19 treatment, cells were analyzed for F-actin density by flow cytometry as described above. For imaging, cells were fixed in 1% PFA, permeabilized with 0.1% Triton-X supplemented with 5% FBS, washed with PBS supplemented with 5% FBS, and then stained with 1 U/ml phalloidin-Alexa Fluor 488 (AF488) (Life Technologies, Beaverton, OR) in PBS supplemented with 5% FBS. The cells were washed, stained with 1 g/ml 4=,6-diamidino-2-phenylindole (DAPI) (Life Technologies, Beaverton, OR), and washed again. After the second wash, the cell pellets were resuspended in Gelvatol mounting medium and mounted onto microscope slides for imaging. Images were collected using a Nikon A1 R spectral confocal microscope with a 100ϫ (1.4 numerical aperture [NA]) oil immersion objective. Following collection using NIS-Elements software, images were parsed to Imaris (Bitplane) and rendered in three dimensions. The total actin volume in each cell was calculated following surface extraction and volume rendering in Imaris.
Quantification of cellular dNTP concentrations. Cellular deoxynucleoside triphosphates (dNTPs) were extracted from 5 to 8 million cells and quantified as described previously (39) .
Reactivation of latent HIV-1 from T N and T CM CD4 ؉ T cells. Seven days postinfection, the T N and T CM CD4 ϩ T cells were washed with medium and plated in a 96-well plate at a density of 100,000 cells/well. Anti-CD3/CD28 antibodies (3 beads per cell; Life Technologies), 10 nM phorbol myristate acetate (PMA; Sigma-Aldrich) with 10 g/ml PHA (PMA-PHA) (Remel), 5 M prostratin, or 500 nM suberoylanilide hydroxamic acid (SAHA; Cayman Chemicals) was then added to the well. Unstimulated cells were used as a control. At 3 and 7 days poststimulation, IL-2 and EFV were added to each well. To evaluate the decay of HIV-1-infected cells following latency reversal, HIV-1 DNA was quantified by qPCR, and the result was normalized to cell number as described above at each respective time point. The level of HIV-1 DNA/cell in unstimulated control cells was normalized to 100 for each donor. The level of HIV-1 DNA/cell following treatment with each latency-reversing agent (LRA) was then normalized to the level of HIV-1 DNA/cell from the unstimulated control cells. The log 10 of each value was then plotted on a linear scale to generate linear regression curves and decay rates.
Extraction and quantification of extracellular virion-associated HIV-1 RNA. Culture supernatant was centrifuged at 16,100 ϫ g for 70 min to pellet HIV-1 virions. Viral RNA was then extracted using an RNeasy Plus minikit (Qiagen), and quantified using a real-time reverse transcriptase (RT)-initiated PCR assay with single-copy sensitivity, as de- 
RESULTS
Direct HIV-1 infection of CD4
؉ T N and T CM cells. Given the low infection frequency of HIV-1 in individuals on ART, it is difficult to use patient-derived cells to perform detailed in vitro analyses. Therefore, we first sought to establish appropriate in vitro primary cell models of HIV-1 latency in CD4 ϩ T N and T CM cells. To maintain the integrity and authenticity of the T N and T CM cell populations, we considered only approaches that avoided significant T cell manipulation, including antigen stimulation or T cell differentiation. Following a review of several approaches, we expanded on the assay system developed by Saleh et al., which uses the chemokine CCL19 to enhance the permissiveness of resting CD4 ϩ T cells to HIV-1 infection (29) . Because prior published studies using this model had characterized the establishment and reversal of HIV-1 latency only in total resting CD4 ϩ T cells (28, 29, 41) , we first quantified the ability of X4-tropic (HIV-1 LAI ) and R5-tropic (HIV-1 BaL ) strains of HIV-1 to infect highly purified CD4 ϩ T N and T CM cells (Fig. 1A) in the absence and presence of CCL19 (Fig.  1B) . Both cell types were equally resistant to both HIV-1 LAI and HIV-1 BaL infection in the absence of CCL19 (Fig. 1C and D) . We found that CCL19 significantly enhanced infection of both T N (Fig. 1C) and T CM (Fig. 1D ) cells by HIV-1 LAI , as assessed by quantification of total HIV-1 DNA. However, T CM cells were more efficiently infected (mean fold increase, 15.5) than were the T N cells (mean fold increase, 3.65). CCL19 was also found to increase the ability of HIV-1 BaL to infect T CM , but not T N , cells ( Fig. 1C and   D ). The result with T N cells could be due to low surface expression of CCR5 on T N cells, which was not affected by exposure to CCL19 (Fig. 2) . CCL19 expression also did not affect expression of CCR5 on T CM cells or CXCR4 expression on either cell type (Fig. 2) . A small percentage of HIV-1 reverse transcripts that fail to integrate are converted to two-long terminal repeat (2-LTR)-containing circles (42), and we accordingly quantified HIV-1 circle levels as a surrogate for unintegrated HIV-1 DNA (Fig. 1E and F) . As expected, this analysis revealed that 2-LTR circles constituted only a minor proportion of the total intracellular HIV-1 DNA of both subsets. Moreover, the relative levels of 2-LTR circle DNA mimicked total HIV-1 levels across the different conditions of virus infection (Fig. 1) .
Finally, we determined whether CCL19 or direct HIV-1 infection induced T cell activation or cellular proliferation of the purified T N or T CM cells (Fig. 3) . We found that CCL19 treatment did not upregulate surface expression of the T cell activation marker CD25, CD69, or HLA-DR (Fig. 3A) . However, a slight increase in CD25 expression was observed in all cells after 7 days of culture, which could not be attributed to HIV-1 infection (Fig. 3A) . There was also no evidence of T cell proliferation as assessed by quantification of total cell number (Fig. 3B) or by intracellular staining of Ki-67 (Fig. 3C) . Additionally, exposure of the T N and T CM CD4 ϩ T cells to CCL19 or HIV-1 did not induce cell death (Fig. 3D) .
Genomic distribution of HIV-1 integration sites in CD4 ؉ T N and T CM cells. We next compared the genomic distribution of HIV-1 integration sites in infected T N and T CM cells and, as a control, compared these values to those obtained using total CD4 ϩ T cells that were broadly stimulated by treatment with phytohemagglutinin (PHA). A total of 729, 2,260, and 133,697 unique integration sites were mapped in the CD4 ϩ T N , T CM , and PHAactivated cells, respectively, with regard to several genomic annotations, including RefSeq genes, transcriptional start sites (TSSs), CpG islands, and gene density ( Table 2 ). The statistical relevance of the observed frequencies versus a matched random control (MRC) data set was determined by Fisher's exact test for RefSeq ). In contrast, the frequency of gene targeting across the different infection conditions was largely similar, with only minor differences noted for the comparisons between T CM and PHA-stimulated cells and between T N and T CM cells ( Table 2) . Integration into gene-dense regions of chromosomes was similarly highly significant compared to random, whereas the differences between infected cell data sets were largely similar (P values from 0.0002 to 0.05). As expected (44), the numbers of HIV-1 integration sites nearby CpG islands or TSSs in CD4 ϩ T N and T CM cells were similar to the MRC value although small but significant differences were noted between the MRC and PHA-activated cells ( Table 2) .
CCL19-mediated HIV-1 infection of CD4 ؉ T N and T CM cells is not due to an increase in F-actin density.
The actin cytoskeleton is known to be a key regulator in many early events of HIV-1 infection, including viral entry, reverse transcription, intracellular trafficking, and integration (45) (46) (47) (48) . In resting CD4 ϩ T cells, cortical actin is static and is restrictive to HIV-1 infection due to actin and its regulators being in an inactive state. Additionally, Cameron et al. reported that CCL19 enhanced HIV-1 infection of resting CD4 ϩ T cells via rapid dephosphorylation of cofilin and changes in filamentous actin (F-actin) density (28) . To validate the role of F-actin density in HIV-1 infection, we first isolated total resting CD4 ϩ T cells and exposed them to different concentrations of latrunculin A (Lat-A), a natural product that prevents F-actin assembly, for 6 h prior to the addition of CCL19 (Fig. 4A) .
Forty-eight hours later, cell viability ( Fig. 4C ) and F-actin density (Fig. 4B) were measured by live/dead and phalloidin staining, respectively, and by flow cytometry. After the 48-h treatment, cells were infected with HIV-1 LAI and cultured for 7 days (Fig. 4A) . HIV-1 LAI infection was then assessed by quantification of total HIV-1 DNA (Fig. 4D) . Lat-A decreased F-actin density in a dosedependent manner, as determined by phalloidin staining intensity (Fig. 4B) , but did not impact cell viability (Fig. 4C) . Importantly, the decrease in F-actin density correlated with a decrease in the ability of HIV-1 LAI to infect the resting CD4 ϩ T cells (Fig. 4D ). In light of these findings, we next used confocal microscopy ( Fig. 5A and B ) and flow cytometry (Fig. 5C ) to evaluate whether exposure of T N and T CM cells to CCL19 increased F-actin density. As described by Permanyer et al., we observed a higher baseline of F-actin density in T CM cells than in T N cells ( Fig. 5B and C) (47) . However, we found no evidence that CCL19 increased F-actin density in either T cell subset after incubation with the chemokine for 2 days (Fig. 5B and C) . It should be noted that Cameron et al. observed a rapid increase in F-actin density within only a few minutes of exposure to CCL19, but after 30 min no significant differences were noted (28) . Collectively, these data suggest that the very transient CCL19-mediated increase in F-actin density, reported previously, cannot explain the increased permissiveness of resting CD4 ϩ T cells to HIV-1 infection 48 h post-chemokine exposure.
CCL19 does not alter intracellular dNTP levels in CD4 ؉ T N or T CM cells. The sterile alpha motif (SAM) and histidine/aspartic acid (HD) domain-containing protein 1 (SAMHD1) imposes an effective restriction to HIV-1 infection in resting CD4 ϩ T cells by enzymatically decreasing cellular dNTP pools and impeding HIV-1 reverse transcription (49-51). It has previously been shown that exogenous addition of dNTPs to resting, naive, or memory CD4 ϩ T cells significantly enhances reverse transcription and viral integration without inducing T cell activation (52, 53) . Therefore, we examined whether CCL19 could increase intracellular dNTP levels, which in turn would facilitate HIV-1 reverse transcription and viral infection of T N and T CM cells. Nucleotide levels in the T N and T CM cells were much lower than those in anti-CD3/CD28-activated cells (Table 3) . However, treatment of T N or T CM cells with CCL19 did not increase the intracellular dNTP levels compared to those of the untreated controls (Table  3) , which suggests that CCL19 does not enhance HIV-1 infection of T N and T CM cells by increasing the nucleotide pool concentration.
Reactivation of HIV-1 LAI from CD4 ؉ T N and T CM cells. We next quantified total virus production (i.e., extracellular virionassociated RNA [vRNA] in the culture supernatant) from latently infected T N and T CM cells using an ultrasensitive assay capable of single-copy detection of HIV-1 RNA (40, 54) before and after exposure to the following latency-reversing agents (LRAs): (i) anti-CD3/CD28 antibodies (3 beads per cell), (ii) 10 nM phorbol 12-myristate 13-acetate (PMA) plus 10 g/ml PHA, (iii) 5 M prostratin, or (iv) 500 nM suberoylanilide hydroxamic acid (SAHA) (Fig. 6A) . As expected, we saw more total virus production from T CM cells than from the T N cells (Fig. 6B) , which is consistent with the observation that the T CM population contained significantly higher levels of HIV-1 DNA.
To account for differences in HIV-1 infection frequency between the T N and T CM cell subsets, as well as between different donors, we normalized extracellular vRNA production to the total HIV-1 DNA copy number/cell at each respective time point (Fig.  6C) . Surprisingly our data revealed that T N cells exposed to anti-CD3/CD28 antibodies, PMA-PHA, or prostratin yielded as much (or more) vRNA as the T CM cells (Fig. 6C) . For example, at day 10 the median production of extracellular HIV-1 LAI vRNA after exposure to anti-CD3/CD28 antibodies, PMA-PHA, or prostratin was 69.7, 71.5, and 29.6 vRNA copies/infected cell from T N cells, compared to 18.8, 57.2, and 21.2 vRNA copies/infected cell from T CM cells, respectively. There was, however, significant variation between donors (Fig. 6D) . For example, in donors 2, 4, 5, and 6, more extracellular HIV-1 LAI vRNA was produced from the T N cells, whereas more HIV-1 LAI was produced from the T CM cells of donor 3 (Fig. 6D) . Collectively, these data suggest that donor genetic differences, in addition to the resting CD4 ϩ T cell compartment, impact the establishment and reversal of HIV-1 latency. In contrast to the other LRAs, SAHA did not significantly increase vRNA production in either T N or T CM cells ( Fig. 6B and C) . This finding is consistent with recent studies that demonstrated the inability of SAHA to increase extracellular HIV-1 production from resting CD4 ϩ T cells isolated from infected individuals on suppressive ART (55) (56) (57) .
Many HIV-1 reverse transcripts fail to integrate, resulting in the accumulation of viral DNA that has the potential to persist in 
resting CD4
ϩ T cells (58) (59) (60) (61) . To exclude the possibility that some forms of this unintegrated HIV-1 DNA become integrated upon T cell activation, resulting in productive infection and virus particle production, we next assessed the contribution of unintegrated HIV-1 LAI DNA to extracellular vRNA production from both T N and T CM cells by including the integrase inhibitor raltegravir (RAL) at the same time as anti-CD3/CD28 (Fig. 6E and F) . This analysis suggested that unintegrated viral DNA did not significantly contribute to the extracellular vRNA quantified in the supernatant following reversal of latency in our model system.
Reactivation of HIV-1 BaL from CD4
؉ T N and T CM cells. We also evaluated extracellular HIV-1 BaL RNA production from infected T N and T CM cells exposed to the same LRAs; however, we excluded SAHA, given that we did not see an effect in our previous experiments ( Fig. 6B and C) . HIV-1 BaL vRNA was produced from T CM cells, with no differences noted compared to production by HIV-1 LAI (Fig. 7) . In contrast, almost no detectable HIV-1 BaL vRNA was produced from the T N cells (Fig. 7) . However, as shown by the data in Fig. 1 , these cells were largely refractory to infection by HIV-1 BaL .
Decay of HIV-1 LAI -infected CD4
؉ T N and T CM cells after exposure to latency-reversing agents. We next measured the decay (Fig. 8B) . No decay was observed in either T N or T CM cells treated with SAHA. Of note, the anti-CD3/CD28 antibodies, PMA-PHA, and prostratin all induced cell activation in both T cell subsets, as evidenced by increased expression of CD69, CD25, and HLA-DR (Fig. 8C) . The levels of cellular activation were also similar between T N and T CM cells and likely do not contribute to the differences observed in virus production between these cell types.
DISCUSSION
Latently infected resting CD4 ϩ T cells constitute the major reservoir of persistent HIV-1 infection, and significant reduction or elimination of this reservoir could lead to either a functional or sterilizing cure, respectively. It has been hypothesized that therapeutic approaches that reactivate latent HIV-1 infection will promote death of the infected cell by viral cytopathic effects and/or by host cell effector mechanisms (62) . This strategy is typically referred to as the "kickand-kill" approach (63) . The resting CD4
ϩ T cell population, however, is heterogeneous and consists of different T cell subsets, including naive and memory cells. It is not known whether the kick-and-kill approach will be equally effective in the different T cell subsets, which differ in life span, proliferative capacity, antigen response time, residence throughout the body, and CCR5 and CXCR4 expression levels (22) (23) (24) . Therefore, mechanistic insights into the establishment and reversal of latent HIV-1 infection in different resting CD4 ϩ T cell subsets could provide important clues to eradicating this persistent reservoir.
In this study, we compared the establishment and reversal of HIV-1 latency in resting CD4 ϩ T N and T CM cells using a primary cell model of latency that utilizes direct infection of highly purified cells. Prior studies demonstrated that HIV-1 latency could be established in vitro in resting CD4 ϩ T cells pretreated with chemokines that bind to the CCR6, CCR7, or CXCR3 receptor (28) .
From an important biological perspective, the concentration of CCL19 (the chemokine ligand for CCR7 used in this study) significantly increases during the acute phase of HIV-1 infection in which the latent reservoir is established and correlates with disease progression (64) (65) (66) (67) . Furthermore, pretreatment of T N or T CM cells with CCL19 does not induce T cell activation or proliferation (Fig. 3) . Thus, the integrity of the purified T cell subsets is largely preserved in the experiment, which was an important prerequisite for the objectives of this study. We show that CCL19 pretreatment of T N and T CM cells significantly increased the capacity for X4-tropic HIV-1 to infect these cells (Fig. 1) . However, as reported in other in vitro systems (10, 53, 68) , the levels of HIV-1 infection in the T CM cells, as assessed by quantitation of total viral DNA, were higher than in the T N cells. In contrast, CCL19 increased R5-tropic virus infection of only T CM cells and not T N cells, a finding which may be attributable to the extremely low levels of CCR5 expression on T N cells isolated from healthy donors (Fig. 2) . Interestingly, several studies have demonstrated that R5-tropic virus can be isolated from CD4 ϩ T N cells from HIV-infected individuals (15, 17, 69, 70) . There are two possible explanations that could account for the discrepancies between in vitro studies and the in vivo observations: (i) HIV-1 infection systematically upregulates CCR5 expression on T N cells, thus making them more susceptible to infection (71) (72) (73) (74) , and/or (ii) R5-tropic virus may be more efficiently transferred to T N cells by plasmacytoid dendritic cells (75) (76) (77) . Further studies, however, are needed to elucidate the mechanism(s) by which T N cells become infected in vivo.
We also attempted to address the mechanism by which CCL19 increases the ability of HIV-1 to infect T N and T CM cells. In this regard, Cameron et al. (28) reported that ligation of the CCR6, CCR7, and CXCR3 receptors led to changes in cortical actin, allowing rapid migration of the preintegration complex to the nucleus and efficient nuclear localization and integration. While our data show a critical role for F-actin density in the ability of HIV-1 to infect resting CD4 ϩ T cells (Fig. 4 ) and suggest that T N cells may be less susceptible to HIV-1 infection than T CM cells due to a lower F-actin density, as reported previously (46, 47) , our comprehensive imaging and flow cytometry data do not support a role for CCL19 in increasing F-actin density in either cell type (Fig. 5) . SAMHD1 has also been identified as an effective restriction factor to HIV-1 infection in resting CD4 ϩ T cells by enzymatically decreasing cellular dNTP pools and impeding HIV-1 reverse transcription (22, 49, 51, 78) . Interestingly, blockade or degradation of SAMHD1 has been shown to greatly enhance the susceptibility of resting CD4
ϩ T cells to HIV-1 infection, especially in T N cells (50, 68) . These findings are consistent with earlier studies showing that addition of dNTPs to T N or memory cells significantly enhanced reverse transcription and integration (52, 53) . In this study, we found that CCL19 does not alter intracellular dNTP concentrations and that HIV-1 can infect both T N and T CM cells despite low nucleotide concentrations. Collectively, these data suggest that CCL19 pretreatment could potentially impact an as yet undocumented restriction factor in resting CD4 ϩ T cells. An unexpected finding from this study was that T N cells exposed to LRAs produced as much (if not more) extracellular virion-associated RNA per infected cell as the T CM population (Fig.  6 ). This observation was found to be independent of the LRA used. These data would suggest that more latently infected T N cells could produce virus than T CM cells. However, we observed no major differences in the genomic distribution of HIV-1 integration sites between the two T cell subsets. Given these differences in virus production between T N and T CM cells, we also evaluated whether HIV-1 reactivation resulted in death of the infected cell. We found that the rates of decay of the HIV-1-infected cells in the T N and T CM populations treated with anti-CD3/CD28 antibodies, PMA-PHA, or prostratin were largely equivalent (Fig. 7) . Using a (79) . Our data support this finding. However, Shan et al. (79) reported that following administration of SAHA, which does not induce T cell activation, the HIV-infected resting CD4
ϩ T cell population survived, even in the presence of autologous cytolytic T lymphocytes. In other words, SAHA facilitated the kick but not the kill. In contrast, we observed that SAHA promoted neither reactivation of latent HIV-1 nor death of the infected cell. Alternatively, in both primary cell models of latency, the decrease in frequency of HIV-1-infected cells could be due to preferential expansion of only the uninfected cell population after T cell activation.
In conclusion, this study highlights the differences in regard to the establishment and reversal of HIV-1 latency in T N and T CM cells. Importantly, the data reveal that despite low infection frequency, T N cells produce as much (if not more) extracellular virion-associated vRNA per infected cell as T CM cells. This suggests that T N cells may be an important reservoir of latent HIV-1 infection and should not be ignored simply because the frequency of infection of these cells is lower than that in the memory T cell subsets in infected individuals on ART. Importantly, we have presented a novel approach to study HIV-1 latency in a primary cell model, focusing specifically on CD4 ϩ T N and T CM cell subsets that can further be used to understand the establishment, maintenance, and reversal of latency in both subsets.
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